Insys Therapeutics, Inc. (NASDAQ:INSY) on 29 may announced it has submitted a Type II Drug Master File (DMF) to the Food and Drug Administration (FDA) for its cannabidiol (CBD) active pharmaceutical ingredient and has been issued DMF# 28255. Insys recently announced plans to advance development of its pharmaceutical CBD program for the treatment of epilepsy in children and adults. Insys Therapeutics Inc. (NASDAQ:INSY) net profit margin is 36.90% and weekly performance is -2.97%. On last trading day company shares ended up $25.84. Analysts mean target price for the company is $52.50. Insys Therapeutics Inc. (NASDAQ:INSY) distance from 50-day simple moving average (SMA50) is -29.38%.
Curis, Inc. (NASDAQ:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, on 23 may announced that its collaborators, Roche/Genentech and Debiopharm Group™ will present results from clinical studies of Erivedge® and Debio 0932, respectively, at the 50th Annual Meeting of American Society of Clinical Oncology (ASCO) to be held from May 30th to June 3rd in Chicago, IL. Curis, Inc. (NASDAQ:CRIS) shares fell -5.32% in last trading session and ended the day on $1.78. CRIS gross Margin is 98.70% and its return on assets is -17.20%.Curis, Inc. (NASDAQ:CRIS) quarterly performance is -41.64%.
Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) announced that Paul Berns the company’s President and Chief Executive Officer will provide a company overview at the Jefferies 2014 Global Healthcare Conference on Monday June 2 2014 at 3:30 p.m. ET in New York New York. Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) shares moved down -5.06% in last trading session and was closed at $13.50, while trading in range of $13.48 – $14.35. Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) year to date (YTD) performance is -19.55%.
NovaBay Pharmaceuticals Inc. (NYSEMKT:NBY) on 28 may announced it has completed patient enrollment in its global phase 2b trial, BAYnovation, testing its solution to treat adenoviral conjunctivitis. NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) ended the last trading day at $0.880. Company weekly volatility is calculated as 13.46% and price to cash ratio as 3.41.NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) showed a negative weekly performance of -1.10%.
Onconova Therapeutics (NASDAQ:ONTX) posted its quarterly earnings results on 12 may. The company reported ($0.87) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.78) by $0.09, Stock Ratings Network.com reports. Onconova Therapeutics Inc. (NASDAQ:ONTX) weekly performance is 5.43%. On last trading day company shares ended up $4.85. Analysts mean target price for the company is $11.50. Onconova Therapeutics Inc. (NASDAQ:ONTX) distance from 50-day simple moving average (SMA50) is -15.29%.